文献速递前列腺癌

复发或转移性激素敏感性前列腺癌患者对阿帕他胺与恩扎卢胺的偏好:一项开放标签随机交叉试验

Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial.
PubMed 文献 · Eur Urol Oncol · 2024-04-22

这项前瞻性开放标签随机交叉试验纳入74例复发或转移性激素敏感性前列腺癌患者,随机接受阿帕他胺(A)与恩扎卢胺(E)各12周,中间洗脱5周。完成两药治疗者66例(89.1%),偏好A超过E的差异为17.8%,医生和照护者分别为18.2%和22.4%。副作用较少是影响偏好的最关键因素,其中乏力较少是A优于E最常报告的优势。

要点

  • 患者偏好阿帕他胺超过恩扎卢胺的差异为17.8%,医生为18.2%,照护者为22.4%。
  • 副作用较少是影响患者偏好的最关键因素,乏力较少是阿帕他胺优于恩扎卢胺最常报告的优势。
  • 两药生活质量无显著差异;研究因中期分析提前终止,结果可能非确定性。

核心结论

  • 在主要为低体积复发或转移性前列腺癌患者及其医生和照护者中,存在偏好阿帕他胺超过恩扎卢胺的趋势。
  • 副作用较少是影响他们选择的最关键因素。

研究设计与样本

  • 前瞻性、开放标签、随机交叉试验。
  • 纳入复发局限性前列腺癌或非高危/高体积转移性疾病且持续雄激素剥夺治疗的患者。
  • 共74例患者符合 eligibility 标准并随机分配至A→E或E→A组,66例(89.1%;32例A→E,34例E→A)完成研究。
  • 所有受试者接受阿帕他胺(A)和恩扎卢胺(E)各12周试验,中间洗脱5周,用药顺序随机。

主要发现

  • 完成两种药物治疗各12周后,偏好A超过E的差异为17.8%。
  • 医生偏好A超过E的差异为18.2%,照护者为22.4%。
  • 副作用较少是影响患者偏好的最关键因素。
  • 在副作用中,乏力较少是A优于E最常报告的优势。
  • 两种药物之间生活质量无显著差异。

局限性

  • 研究因中期分析提前终止,结果可能非确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Treatment preference regarding apalutamide versus enzalutamide in prostate cancer (PCa) and the factors influencing decisions are largely unknown. Our aim was to investigate the preference for apalutamide versus enzalutamide among prostate cancer patients and their physicians and caregivers, and factors influencing their decision. METHODS: This was a prospective, open-label, randomized, crossover trial. Patients with recurrence of localized PCa or with metastatic disease not considered as high-risk or high-volume and on continued androgen deprivation therapy were recruited. All subjects received a trial of two agents, apalutamide (A) and enzalutamide (E), for 12 wk each, with a 5-wk washout period in between. The sequencing of the drugs was randomized. The primary outcome was patient preference for one the drugs, assessed at the end of the study. Other outcomes included factors influencing patient preference, a comparison of side-effect profiles, and patients' quality of life (QoL). Physician and caregiver preferences for the drugs and factors affecting their choice were also assessed. KEY FINDINGS AND LIMITATIONS: A total of 74 patients met the eligibility criteria and were randomized to the A → E or E → A arm. Of these, 66 patients (89.1%; 32 A → E, 34 E → A) completed the study. Baseline characteristics were comparable between the two groups, and ∼90% of the patients had low-volume metastatic disease. After completion of both treatments for 12 wk each, the difference in preference for A over E was 17.8%, with similar trends for preference of A over E among physicians (18.2%) and caregivers (22.4%). Fewer side effect was the most critical factor influencing the preference of patients. Among the side effects, less fatigue was the benefit of A over E most frequently reported. No notable difference in QoL was observed between the two drugs. However, the study was terminated on interim analysis and the results might not be conclusive. CONCLUSIONS: There was a trend for preference of A over E among patients with predominantly low-volume recurrent or metastatic PCa and their physicians and caregivers. Fewer side effects was the most critical factor influencing their choice. PATIENT SUMMARY: Patients with low-volume recurrent or metastatic prostate cancer tended to prefer treatment with apalutamide over enzalutamide. Side effects were the most critical factor influencing treatment preference.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ng CF, Yee CH, Chiu PK, et al. Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial. Eur Urol Oncol. 2024. PMID: 38653621. doi:10.1016/j.euo.2024.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。